Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc. | Sunosi (Solriamfetol) - (SHARP) | Excessive Daytime Somnolence (EDS), Obstructive Sleep Apnea (OSA) | Phase 3 | Trial Completed | Oral | Neurology |
| Axsome Therapeutics Inc. | Reboxetine (AXS-12) - (ENCORE) | Narcolepsy | NDA Filing | Data Released | Oral | Neurology |
| Axsome Therapeutics Inc. | Dextromethorphan-bupropion (AXS-05) - (MERIT) | Treatment resistant depression | Phase 2 | Data Released | Oral | Psychiatric |
| Axsome Therapeutics Inc. | Dextromethorphan-bupropion (AXS-05) | Smoking cessation | Phase 2/3 | Data Released | Oral | Anti-Addiction |
| Axsome Therapeutics Inc. | Sunosi (Solriamfetol) - (FOCUS) | Attention deficit hyperactivity disorder (ADHD) | Phase 3 | Data Released | Oral | Psychiatric |
| Axsome Therapeutics Inc. | Sunosi (Solriamfetol) - (PARADIGM) | Major depressive disorder (MDD) | Phase 3 | Ongoing | Oral | Psychiatric |
| Axsome Therapeutics Inc. | AXS-05 (ADVANCE-2) | Alzheimer's disease agitation | Phase 3 | Data Released | Oral | Psychiatric |
| Axsome Therapeutics Inc. | SYMBRAVO (MoSEIC meloxicam-rizatriptan (AXS-07)) - (EMERGE) | Migraine | Phase 3 | Data Released | Oral | Neurology |
